Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Drug resistance is a major cause for therapeutic failure in non-small cell lung cancer (NSCLC) leading to tumor recurrence and disease progression. Cell intrinsic mechanisms of resistance include changes in the expression of drug transporters, activation of pro-survival, and anti-apoptotic pathways,...
Main Authors: | Venus Sosa Iglesias, Lorena Giuranno, Ludwig J. Dubois, Jan Theys, Marc Vooijs |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00267/full |
Similar Items
-
Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells
by: Venus Sosa Iglesias, et al.
Published: (2018-11-01) -
Notch Inhibition in Cancer: Challenges and Opportunities
by: Doriano Fabbro, et al.
Published: (2020-10-01) -
Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases
by: Panagiotis F. Christopoulos, et al.
Published: (2021-04-01) -
Inhibition of Notch signaling in combination with paclitaxel reduces platinum-resistant ovarian tumor growth
by: Jolijn W Groeneweg, et al.
Published: (2014-07-01) -
Taming the Notch Transcriptional Regulator for Cancer Therapy
by: Luca Tamagnone, et al.
Published: (2018-02-01)